Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Accelerated Hecolin Schedule in Adults
NCT03168412Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- May 2017
- Primary completion
- Jul 2018
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of HEV 239 in hepatitis E (HEV) (2 arms), sponsored by Xiamen Innovax Biotech Co., Ltd. Primary endpoint: Anti-HEV antibody of Experimental Group at 2 months. Started May 2017; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT03168412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168412.